The Core Technology for Vaccine Development of GeneMatrix
The Core Technology for High-Efficiency Novel Vaccine Development
Zika virus infection is a mosquito-borne viral infection that have been linked to the occurrence of severe congenital anomalies in pregnant women such as microcephaly in fetus since the outbreak in Central and South America including Brazil in 2015. Global health-related organizations such as WHO and CDC are also investing in large-scale budgets to prevent and treat the disease.
However, new characteristics which is not common in the same family of viruses, such as the possibility of sexually transmitted infections and neuronal cell affinity continue to be discovered and there is no clear treatment until now. Therefore the importance of development of a rapid vaccine to prevent infection is getting bigger as the only alternative.
We are conducting research and development in cooperation with Korea Centers for Disease Control and Prevention and Kangwon National University in order to develop vaccine substance candidates and efficacy evaluation system for Zika virus.
We are developing effective vaccine candidates and assessing efficacy based on our patented high immunogenicity recombinant antigen production technology, recombinant protein refolding solubilization technology and antibody selection screening technology. In addition to the Zika virus, our technologies are utilized to develop premium vaccines for various infections such as Dengue.
Development Status of ZIKA Recombinant Vaccine
ZIKA Recombinant Vaccine
Development of vaccine candidates
Vaccine candidate development technology
Target selection of vaccine candidate (antigen)
Selection of recombinant antigen expression host
Recombination of the candidate gene
Recombinant antigen expression and purification
Large-scale antigen purification for validation
Evaluation of the effectiveness of the vaccine candidate (Animal model)
Humoral immunity assessment using animal models
Cellular immunity assessment
Evaluation of vaccine response
Selection of optimal vaccine candidates
Non-clinical trial of the vaccine candidate
Non-clinical toxicity test
General pharmacological test
Clinical trial of the vaccine candidate
Clinical trial production of the vaccine candidate
Clinical trial (Phase I, II, and III)
Product registration approval
Establishment of recombinant antigen expression, purification and production process
Validation using animal models
Clinical trials and approval
A composition for refolding recombinant protein, a refolding method using the same, and a production method of recombinant antigen using the same (Application No. 10-2016-0026434)
A monoclonal antibody for specifically binding heart-type fatty acid binding protein and hybridoma cell producing the same, and a method for preparing the same (Application No. 10-2016-0050308)
Vaccine: Classification by antigen
Vaccine is a medicine that activates the immune system by injecting into the body in advance to prevent infectious diseases. When the vaccine is administered, the body recognizes the vaccine as a pathogen and makes an antibody in the body. By forming a memory cell for the antigen, when the actual pathogen comes in, the body can quickly defend the pathogen by neutralizing it by the secondary immune response.
Vaccines include ones with inactivated pathogens and live vaccines with attenuated pathogens. Also as genetic engineering technology evolves, recombinant vaccines and DNA vaccines were also developed.
It is a type of vaccine that is produced by inactivating all or part of viruses and bacteria with chemical or heat, and it includes hepatitis A, pertussis, typhoid, and cholera vaccines.
Live attenuated vaccine
It is a type of vaccine with altered parts of viruses or bacteria that have the ability to self-replicate and induce immunity but eliminated toxicity. It includes measles, mumps and rotaviruses vaccines.
It is a type of vaccine with a special form of inactivated subunit consisting of a long-chain of sugar molecule that produces a surface capsule of specific bacteria. It includes pneumococcal and typhoid vaccines.
It is a type of vaccine that utilizes recombinant technology to recombine parts of the virus's entire genes. In recombination, different strain or cell expression system than the original virus is used.